Alexis Ogdie - Faculty Biosketch

Alexis Ogdie, MD, MSCE

Professor of Medicine (Rheumatology) at the Hospital of the University of Pennsylvania

Director, Penn Psoriatic Arthritis Clinic, University of Pennsylvania, Philadelphia, PA

Worker Without Compensation (WOC), Philadelphia VA Medical Center, University of Pennsylvania, Philadelphia, PA

Senior Scholar, Penn Center for Clinical Epidemiology and Biostatistics

Director, Penn Center for Clinical Epidemiology and Biostatistics

3 5f

Department: Medicine

4 1 23

1f Graduate Group Affiliations 8

Graduate Group in Epidemiology and Biostatistics

46 Contact information
40

3400 Spruce Street
18 5 White Building
52 Hospital of the University of Pennsylvania
Philadelphia, PA 19104-4283

2e Office: 215-662-2454
32 Fax: 215-662-4500
24

4 3 3 3 2 4 b 1f

13 Education:
21 7 BS c
30 University of Minnesota, 2002.
21 7 MD c
41 Georgetown University School of Medicine, 2006.
21 9 MSCE c
33 University of Pennsylvania, 2012.
c

3 3 21

1f Post-Graduate Training
24 5e Intern in Medicine, University of Pennsylvania, Philadelphia, PA, 2006-2007.
24 54 Resident, University of Pennsylvania, Philadelphia, PA, 2007-2009.
24 61 Fellow, Rheumatology, University of Pennsylvania, Philadelphia, PA , 2009-2011.
24 69 Fellow, Clinical Epidemiology, University of Pennsylvania, Philadelphia, PA, 2010-2011.
c

3 25

17 Certifications
28 50 Internal Medicine - American Board of Internal Medicine, 2009.
28 4b Rheumatology - American Board of Internal Medicine, 2011.
c

3 8d Permanent link
2 29

b6 > Perelman School of Medicine > Faculty > Details a

1e 1d

7 29

Selected Publications

13e Ramiro S, Gaillez C, Kiltz U, Gensler LS, Pisal C, Braun J, Ogdie A.: No major effect of age (< 40 vs. ≥ 40 years) on response to secukinumab in patients with axSpA: a post hoc analysis of six phase 3 trials. Arthritis Res Ther Apr 2026.

263 Romich E, Ogdie A, Stephens-Shields A, Merkel PA, Assassi S, Bernstein EJ, Bujor A, Castelino FV, Chung L, Evnin LB, Frech TM, Gordon JK, Griffith M, Hant FN, Harding ML, Hummers LK, Khanna D, Lakin KS, Lebiedz-Odrobina DJ, Luo Y, Makol A, Mayes MD, McMahan ZH, Molitor J, Moore DF, Paik J, Richardson C, Skaug B, Shah AA, Shah A, Steen V, VanBuren JM, Volkmann ER, Zahn C, Sandorfi N; CONQUER Investigators.: Discordance between patient and physician global assessments in early systemic sclerosis. Arthritis Care Res (Hoboken) Apr 2026.

1c8 Baker JF, Wysham KD, Quinones M, England BR, Jin K, Olave M, Wetzel S, Gillcrist RL, Lavery C, Keller N, Kramer B, Ateh B, Brubeck H, White DK, Ogdie A, Xiao R, Neogi T, Scanzello CR.: Behavioral Incentives for Exercise and Intra-Articular Corticosteroids for Knee Osteoarthritis: Results from a Factorially Designed Pragmatic Randomized Clinical Trial. Arthritis Rheumatol Apr 2026.

172 Nikiphorou E, Ogdie A, Twigg D, Quiñones E, Ling YL, Cappelleri JC, Sanchez-Riera L, Masri KR, Hughes M, Massey N.: Treatment satisfaction, disease severity, and health-care use in patients with axial spondyloarthritis in the United States and Europe. Rheumatology (Oxford) 65: keag106, Mar 2026.

1cc Merola JF, Mease P, Kivitz A, Sattar N, Coates LC, Aletaha D, Kartman CE, Fischer P, Sun L, Martínez-Osuna P, Kronbergs A, Prajapati P, Cardoso A, Genovese MC, Ogdie A.: Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial. Arthritis Rheumatol Mar 2026.

157 Ogdie A, Middaugh N, Marchese M, Walsh JA, Bello N, Ngantcha M, Kronbergs A, Grace EL, Mease PJ.: Cycling to TNFi vs. Switching to IL-17Ai Among Patients with Psoriatic Arthritis and Axial Spondyloarthritis: Real-World CorEvitas PsA/SpA Registry Data. Adv Ther Mar 2026.

1dc Ogdie A, Merola JF, Mease PJ, Ritchlin CT, Scher JU, Lafferty KP, Chan D, Chakravarty SD, Langholff W, Wang Y, Shao J, Krol Y, Gottlieb AB.: Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of the Phase 3, Randomized, Placebo-Controlled SOLSTICE Study. Arthritis Rheumatol Feb 2026.

1ae Mease P, Ye X, Saffore CD, Parikh B, Ciecinski S, Blachley T, Eliot M, Middaugh N, Ogdie A.: Quantifying Disease Activity Despite Treatment with Tumor Necrosis Factor Inhibitors Among Patients with Psoriatic Arthritis and Axial Spondyloarthritis: Real-World Results from the PPD CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Rheumatol Ther 2026.

1c6 Leung YY, Haugegaard T, Annfeldt TK, Holland R, Strand V, Mease P, Tugwell P, Wells GA, Shea BJ, Mathew AJ, Goel N, Lindsay C, Ogdie A, Orbai AM, Coates LC, Gladman DD, Tillett W, Chau J, Christensen R.: Determining the best discriminatory physical functioning outcome measurement instrument for psoriatic arthritis trials: A meta-epidemiological study. Semin Arthritis Rheum 2026.

194 Gladman DD, Eder L, Selmi C, Mease PJ, Ogdie A, Lozenski K, Adamson E, Sharaf M, Rampakakis E, Pina Vegas L, Coates LC.: Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials. Rheumatol Ther Dec 2025.

2c

7 1d

2c back to top
26 Last updated: 04/20/2026
34 The Trustees of the University of Pennsylvania c